- Home
- KTTA vs CANF Comparison
KTTA vs CANF Comparison
Compare KTTA & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- CANF
- Stock Information
- Founded
- KTTA 2020
- CANF 1994
- Country
- KTTA United States
- CANF Israel
- Employees
- KTTA N/A
- CANF N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- CANF Health Care
- Exchange
- KTTA Nasdaq
- CANF Nasdaq
- Market Cap
- KTTA N/A
- CANF 7.9M
- IPO Year
- KTTA 2021
- CANF N/A
- Fundamental
- Price
- KTTA $1.73
- CANF $1.13
- Analyst Decision
- KTTA
- CANF Strong Buy
- Analyst Count
- KTTA 0
- CANF 2
- Target Price
- KTTA N/A
- CANF $14.00
- AVG Volume (30 Days)
- KTTA 5.3M
- CANF 423.1K
- Earning Date
- KTTA 05-13-2025
- CANF 05-06-2025
- Dividend Yield
- KTTA N/A
- CANF N/A
- EPS Growth
- KTTA N/A
- CANF N/A
- EPS
- KTTA N/A
- CANF N/A
- Revenue
- KTTA N/A
- CANF $674,000.00
- Revenue This Year
- KTTA N/A
- CANF $461.72
- Revenue Next Year
- KTTA N/A
- CANF N/A
- P/E Ratio
- KTTA N/A
- CANF N/A
- Revenue Growth
- KTTA N/A
- CANF N/A
- 52 Week Low
- KTTA $0.92
- CANF $1.22
- 52 Week High
- KTTA $7.69
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- KTTA 64.02
- CANF 35.40
- Support Level
- KTTA $1.30
- CANF $1.14
- Resistance Level
- KTTA $1.81
- CANF $1.27
- Average True Range (ATR)
- KTTA 0.24
- CANF 0.12
- MACD
- KTTA 0.05
- CANF -0.02
- Stochastic Oscillator
- KTTA 53.08
- CANF 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).